Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Atorvastatin (Primary) ; Rosuvastatin (Primary)
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Acronyms gRANADa
- 03 Dec 2014 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 according to ClinicalTrials.gov record.
- 03 Dec 2014 Planned initiation date changed from 1 Feb 2014 to 1 Jan 2015 according to ClinicalTrials.gov record.
- 11 Feb 2014 New trial record